In parallel with increasing global burden of atrial fibrillation (AF), accumulating high-quality evidence from randomized clinical trials on AF management inform frequent updates of AF guidelines[@b1]. However, guideline implementation into daily clinical practice might be incomplete for many reasons and monitoring of routine practice through ongoing large, well-conducted long-term registries[@b2][@b3] helps to understand and attenuate barriers for evidence-based management of AF in 'real-world' setting.

Recent reports from contemporary European AF registries have provided important insights into AF management in clinical practice[@b2][@b3][@b4][@b5], including the observation of certain regional differences in management across Europe[@b6]. Most countries from the Balkan Region (comprising an area of \>50 million inhabitants) were not participating in prior registries, and in contrast to other European regions, 'real-world' data on the management of AF in Balkan countries are limited.

In this study, we investigated contemporary real-world patterns of AF management in the Balkan Region through a prospective 14-week survey of consecutive AF patients in clinical practice, and we report the results pertinent to stroke prevention.

Methods
=======

Study design and patient selection
----------------------------------

A detailed report on the Balkan-AF study protocol has been published[@b7]. A 14-week prospective, multicentre 'snapshot' Balkan-AF survey of consecutive patients with electrocardiographically documented AF, who were seen by cardiologists or internal medicine specialists (in centres where a cardiologist was not available), was conducted from December 2014 to February 2015 in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Montenegro, Romania and Serbia (a total of \~40 million inhabitants). The survey was designed and conducted by the Serbian Atrial Fibrillation Association (SAFA), which is a non-profit multidisciplinary association of expert physicians involved in AF management and AF research.

The survey was announced to the National Cardiology Societies and relevant Working Groups or associations in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Former Yugoslav Republic Macedonia, Montenegro, Romania, Slovenia and Serbia. In the participating countries Balkan-AF survey was approved by the national and/or local Institutional Review Board, or the need for approval was waived according to the regulations in the respective country. In concordance with the local policy, a signed patient informed consent was obtained from each patient before enrolment. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.

Each country participated with university and non-university hospitals and outpatient health centres in- and outside the capital cities. Patients younger than 18 years and patients with prosthetic mechanical heart valves or significant valve disease requiring surgical repair were not included.

Data collection
---------------

Data were collected via a web-based electronic case report form (CRF) with a range of pre-specified plausibility checks for the entries. The CRF was formulated to obtain the information on patients' characteristics including demographics, cardiovascular risk factors, medical history, AF-related data regarding symptoms, prior history of AF, AF clinical type, prior use of antithrombotic medication, antiarrhythmic drugs or other therapies, health care setting (i.e., university/non-university health centre, in- or outside the capital city, in-hospital or outpatient, internal medicine specialist/cardiologist, main reason for current visit/hospitalization, emergency or non-emergency setting, length of hospitalization, etc.) and patient's presentation, AF management at enrolling visit or hospitalization (i.e., medication, cardioversion, AF ablation) and further management strategy post discharge, and diagnostic procedures performed due to AF during enrolling visit/hospitalization or within the last 12 months (the latter was not applicable to patients with first-diagnosed AF). A detailed list of cardiovascular risk factors, diseases and risk scores definitions used in the Balkan-AF survey is provided in the [Supplementary Appendix 1](#S1){ref-type="supplementary-material"}.

Systematic monitoring of centres was not performed due to the relatively short duration of the survey. The national coordinators and all investigators are the guarantors of the consecutiveness of enrolment, accuracy and completeness of data. The CRF, patient files, and medical records (paper or database) serve as source documents.

Statistical analysis
--------------------

Following a test of statistical normality, continuous variables were presented as mean with standard deviation (SD), or with a skewed distribution as median with interquartile range (IQR, 25^th^--75^th^ quartile). Categorical variables were reported as counts with percentages. The Student t-test was used for comparison of continuous variables with normal distribution, and Mann-Whitney test for continuous variables with skewed distribution. Differences in categorical variables were tested by Chi-square test.

Univariate and multivariable logistic regression analyses were used to investigate the associations of variables shown in [Table 1](#t1){ref-type="table"} (that is, demographic data, patient clinical characteristics and AF characteristics) and health care setting with the use of oral anticoagulants (OAC) and other antithrombotic therapies (that is, antiplatelet drugs), as prescribed at discharge from enrolling visit or hospitalization. Variables statistically significant on univariate analysis were entered into the multivariable model to identify independent predictors of OAC use. All analyses were adjusted for country code, to account for differences in the health care systems among the participating countries.

Because the main reason for enrolling visit or hospitalization could have been either AF or some other condition, we have performed two sensitivity analyses. First, we excluded patients seen for other reasons (in whom the use of OAC might have been influenced by other condition) and performed the analysis of OAC use as in the main cohort. Second, we excluded patients presenting with an acute coronary syndrome and then performed the OAC use analyses in the rest of the main cohort.

All results are reported as Odds Ratio (OR) with 95% Confidence Interval (CI). All statistical analyses were performed using SPSS 20.0 software package (SPSS Inc., Chicago, Illinois). A two-sided P value of \<0.05 was considered statistically significant.

Results
=======

A total of 2712 patients were enrolled in 49 centres from seven Balkan countries; 27 centres (55.1%) were university hospitals enrolling 2161 patients (86.6%). Eighteen centres (36.7%) were situated in the capital cities and enrolled 1241 patients (45.8%). A total of 2147 patients (79.2%) were enrolled by cardiologists, and 717 patients (26.8%) were seen in outpatient setting. Full data on antithrombotic therapy prescribed at current visit/hospitalization were available in 2663 patients (98.2%) and those patients were included in this analysis.

Demographic data (mean age 69.1 ± 10.9 years, range 18--96; female 44.6%), clinical characteristics of the study population and AF characteristics are shown in [Table 1](#t1){ref-type="table"}.

Stroke and bleeding risk profile
--------------------------------

Mean CHA~2~DS~2~-VASc score was 3.48 ± 1.77 (range 0--9, median 3.0, IQR 2.0--5.0), and a score of ≥2 was present in 2290 patients (86.0%). The mean CHADS~2~ score was 2.15 ± 1.29 (≥2 in 65.6% of patients), and mean HASBLED score was 1.97 ± 1.23 (range 0--6). Country-specific stroke and bleeding risk distribution is shown in [Table 1](#t1){ref-type="table"}, [Fig. 1](#f1){ref-type="fig"} and Supplemental Table 1.

Antithrombotic therapies
------------------------

Country-specific distribution of antithrombotic therapies is shown in [Table 2](#t2){ref-type="table"}. Overall, 264 patients (9.9%) were not given any antithrombotic therapy, 1960 patients (73.6%) were prescribed OAC, and 762 patients (28.6%) received an antiplatelet drug. OAC as only antithrombotic drug was given to 1637 patients (61.5%), whilst an antiplatelet drug only was given to 320 patients (12.0%, and in 91.2% of patients that was aspirin).

NOACs (i.e., dabigatran, rivaroxaban or apixaban) were given to 338 patients (12.7% of the whole study population or 17.2% of patients receiving OAC).

One patient previously underwent a left atrial appendage closure device implantation.

Adherence to guidelines
-----------------------

The proportions of OAC and other antithrombotic therapies by CHA~2~DS~2~-VASc and HASBLED score strata are shown in [Fig. 2](#f2){ref-type="fig"}.

In the 'truly' low-risk group (that is, CHA~2~DS~2~-VASc score of 0 in males, or 1 in females) only 44 patients (33.6%) were not given any antithrombotic therapy, whilst 74 patients (56.5%) received OAC and 18 patients (13.7%) received an antiplatelet therapy, alone or in combination with OAC (3.8%). The use of OAC in 'truly' low-risk patients could be attributed to planned cardioversion or AF catheter ablation in only 21 patients (16.0%).

Of 2290 patients with CHA~2~DS~2~-VASc ≥2, 194 (8.5%) received no antithrombotic therapy, 1401 (61.2%) were given OAC only and 393 patients (17.2%) received an antiplatelet drug alone. A combination of OAC and an antiplatelet drug was given to 302 patients (13.2%).

There was no significant association between the CHA~2~DS~2~-VASc score and OAC prescription on multivariate analysis ([Table 3](#t3){ref-type="table"}). The non-relationship to CHADS~2~ score was similar (OR 1.06; 95% CI, 0.98--1.13, p = 0.119). The use of OAC increased with increasing HASBLED score, but the difference was significant only on univariate analysis (p = 0.042), [Table 3](#t3){ref-type="table"}.

The use of antiplatelet drugs was significantly associated with CHA~2~DS~2~-VASc score only on univariate analysis ([Table 3](#t3){ref-type="table"}).

Determinants of OAC use
-----------------------

Independent predictors of the use of antithrombotic therapies are shown in [Table 3](#t3){ref-type="table"}, including significant univariate associations with the use of OAC or antiplatelet drug only (full univariate analyses list is shown in Supplemental Table 2).

OAC monotherapy
---------------

On univariate analysis, most of the CHA~2~DS~2~-VASc score components were not significantly associated with OAC use, including prior stroke (OR 1.02; 0.76--1.37; p = 0.878). Patients with hypertension were more likely to use OAC, whilst older age (≥80 years) and coronary artery disease (CAD) were inversely associated with OAC use (Supplemental Table 2).

Increasing body mass index (BMI), mitral valve disease, dilated cardiomyopathy and thyroid disease were associated with increased use of OAC, whilst patients with chronic kidney disease (CKD) on dialysis and patients with chronic obstructive pulmonary disease (COPD) were less likely to use OAC (Supplemental Table 2).

The proportions of OAC use according to AF clinical type are shown in [Fig. 3](#f3){ref-type="fig"}. Known history of AF was associated with increased use of OAC, whilst patients with paroxysmal AF were less likely to receive OAC. Patients treated in the health centres situated in the capital city or in university centres and patients managed by a cardiologist were more likely to use OAC compared to other patients (Supplemental Table 2).

Independent predictors of OAC use were hypertension, mitral valve disease, dilated cardiomyopathy, known history of AF and treatment in the capital city health centres, whilst age ≥80 years, prior MI and paroxysmal AF were independent predictors of OAC non-use ([Table 3](#t3){ref-type="table"}).

Antiplatelet drug (aspirin) monotherapy
---------------------------------------

Independent predictors of aspirin monotherapy were age ≥80 years, CAD, aortic valve disease, COPD and paroxysmal AF, whilst BMI, known history of AF and treatment in the capital city health centre or treatment by a cardiologist were negatively associated with aspirin use ([Table 3](#t3){ref-type="table"}). On univariate analysis, increasing CHA~2~DS~2~-VASc score and prior transient ischemic attack (TIA) were also associated with increased use of aspirin only ([Table 3](#t3){ref-type="table"}).

Other antithrombotic therapies
------------------------------

Independent predictors of dual antiplatelet drug therapy (DAPT) use were PCI, any CAD, COPD and paroxysmal AF, whilst patients with known history of AF were less likely to receive DAPT ([Table 3](#t3){ref-type="table"}). Independent predictors of the use of OAC combined with one or two antiplatelet drugs were CAD, PCI and treatment in a hospital-based centre, whilst patients aged ≥80 years were less likely to be given such therapy. Increasing HASBLED score was positively associated with the use of combined therapy ([Table 3](#t3){ref-type="table"}).

Indices of VKA anticoagulation quality
--------------------------------------

An International Normalized Ratio (INR) obtained within previous 3 weeks was available in 946 (79.0%) of 1198 patients who were previously taking a VKA for at least 6 months or longer. The most recent INR value ranged from 1 to 10 (mean 2.42, SD 1.0, median 2.28), and was within the target range of 2.0 to 3.0 in 522 patients (55.2%) whilst in 281 (29.5%) and 143 patients (15.1%) the INR was below and above the target range, respectively.

The Time in Therapeutic Range (TTR) from the previous 3 months was available in only 224 patients (18.7%). Mean TTR was 49.5% ± 22.3% (median 50.0%, range 10--100%) and only 66 patients (29.5%) had a TTR of ≥65%. Labile INR was reported in 439 patients (36.6%) in whom TTR was not available.

Sensitivity analyses
--------------------

AF was the main reason for enrolling visit or hospitalization in 1329 patients (49.9%). Compared to the main cohort, these patients were younger (mean age 66.9 ± 11.3 years), with lower CHA~2~DS~2~-VASc (mean 2.95 ± 1.74) and lower HASBLED score (1.72 ± 1.19), all p \< 0.01. OAC was given to 1000 patients (75.2%). Univariate and multivariable determinants of OAC use in patients with AF as the main reason for enrolling visit or hospitalization are shown in Supplemental Table 4. Similar to the main cohort, there was no significant relationship between the CHA~2~DS~2~-VASc score and the use of OAC in the multivariable analysis. The use of OAC was driven by the presence of hypertension, younger age (\<75 years), increasing BMI, non-cardiac comorbidities (thyroid disease), centre localization (capital city) and university centre type, whilst patients with COPD, malignancy and paroxysmal AF were less likely to be prescribed OAC (Supplemental Table 4).

An acute coronary syndrome was the main reason for enrolling hospitalization in 206 patients (7.7%) and they were excluded from this analysis. In the remaining cohort of 2457 patients (mean age 68.9 ± 11.0 years, mean CHA~2~DS~2~-VASc 3.42 ± 1.77, mean HASBLED 1.97 ± 1.23) OAC was prescribed to 1843 patients (75.0%), and the use of OAC was driven by broadly similar determinants as in the main cohort (Supplemental Table 5).

Discussion
==========

This snapshot survey provides, for the first time, a contemporary insight into routine clinical practice in AF management from a large region of Europe where data on AF management are generally scarce, especially since countries participating in this survey were largely under-represented in recent European AF surveys[@b2][@b4][@b5]. This survey therefore complements the European AF data and reduces a gap in the European 'map' of contemporary real-world management of AF.

Our findings suggest that the overall use of OAC for stroke prevention in the Balkan region is relatively high (\~74%), but poorly associated with individual patient stroke risk as recommended by the European Society of Cardiology guidelines[@b1]. Whilst mostly VKA were used, the quality of anticoagulation was poor, with less than a third of patients having a TTR of ≥65%. Overall, the use of NOACs was slightly higher than recently reported in a 'real-world' European survey[@b3], and the use of antiplatelet drugs was comparably high as in other parts of Europe. We also observed significant differences in the use of antithrombotic therapies according to the physician specialty and health centre location. Our results have important practical implications and may help in recognizing the 'action points' needed to improve the management of AF patients at risk of stroke in daily clinical practice in the Balkan region.

The Balkan-AF cohort stroke risk profile was broadly similar to recent data from the EURObservational Pilot AF Registry[@b3], with some minor differences (e.g., hypertension, diabetes mellitus and prior stroke were slightly more prevalent, whilst CAD, HF and valvular disease were slightly less frequent in the Balkan-AF cohort). However, bleeding risk was higher, and the difference might possibly be driven by labile INRs in many patients.

The overall use of OAC in Balkan-AF cohort was close to that in recent European reports[@b3][@b4], but was not significantly associated with CHA~2~DS~2~-VASc score, even when categorised to \<2 vs. ≥2. Despite clear evidence of low stroke risk in male AF patients with a CHA~2~DS~2~-VASc score of 0 and those with a score of 1 due to female sex[@b8][@b9][@b10][@b11][@b12], in whom no antithrombotic therapy is recommended[@b1], as many as 56.5% of such patients in the Balkan-AF cohort received OAC despite only a minority being scheduled for cardioversion or AF ablation.

Some deviations from evidence-based stroke prevention strategies were evident in the Balkan-AF cohort. For example, elderly patients were more likely to receive aspirin, despite clear evidence of net benefit with OAC in elderly[@b13][@b14]. Also, patients with stable CAD were more likely to receive aspirin or DAPT, or OAC plus antiplatelet drugs instead of OAC monotherapy, although evidence showed that combining OAC with antiplatelet drugs in AF patients with stable vascular disease resulted only in increased risk of major bleeding with no additional reduction of thromboembolism[@b15][@b16]. Such patterns of OAC use were also noted in other European countries[@b6].

Independent predictors of increased OAC use in the Balkan-AF survey were hypertension, dilated cardiomyopathy and mild-to-moderate mitral valve disease (essentially mitral regurgitation). In contrast to mitral stenosis, data on the risk of stroke in AF patients with mitral regurgitation are controversial[@b17] and decisions on OAC should be driven by the presence of well documented stroke risk factors.

The 'chronicity' of AF strongly influenced OAC use in the Balkan-AF cohort, with a 56% lower probability for OAC in paroxysmal AF and a 49% greater probability of OAC therapy in patients with history of AF. A large body of evidence suggests that stroke risk is comparable with paroxysmal or permanent AF[@b18][@b19]. Recently, this has been challenged by a meta-analysis of two non-anticoagulated AF cohorts with systematically adjudicated adverse events which showed AF type to be a strong independent predictor of stroke[@b20], but the annual stroke rate with paroxysmal AF was still sufficiently high (2.1%) to warrant OAC therapy[@b1]. Hence, the decision on OAC should be guided by the presence of conventional stroke risk factors.

The use of aspirin alone was high across all CHA~2~DS~2~-VASc score strata and increased from 10% to 17.2% with increasing score. Despite sufficient evidence of only modest efficacy and similar safety compared to OAC[@b13][@b14], aspirin is still used as monotherapy in around 15% of AF patients in Europe[@b2]. Independent predictors of aspirin use in the Balkan-AF survey (i.e., advanced age, paroxysmal AF, COPD, mild-to-moderate aortic valve disease) likely reflect a mixture of misperceptions of aspirin better safety (e.g., in elderly) or of lower stroke risk (e.g., paroxysmal AF, COPD, etc.) and an unjustified favouring of aspirin over OAC (e.g., in patients with stable CAD or aortic valve disease).

However, the HASBLED score was not a significant determinant of OAC use in our cohort (indeed, the use of OAC increased with increasing HASBLED), suggesting that either the role of HASBLED was correctly interpreted (that is, the score was used to flag up modifiable bleeding risk factors, and not to preclude OAC use) or perhaps the score was ignored. The latter seems to be the case particularly with the use of combined OAC plus antiplatelet drug therapy, which increased with increasing HASBLED score. Alternatively, sicker patients might have needed such therapy more often.

Around 80% of AF patients in our survey were managed by a cardiologist, and these patients were less likely to receive aspirin. Patients managed in health centres in the capital cities less often received aspirin and more often were given OAC, the latter likely resulting from the clustering of tertiary health centres in the capital cities in most of participating countries. Of note, similar influence of clinical background and specialty of treating physicians on antithrombotic treatment strategies in AF patients has been also described in other European countries[@b21]. However, the availability of a cardiologist with proper level of expertise for stroke risk management in AF patients in real-world clinical practice may significantly differ among countries.

The signal of poor quality of anticoagulation with VKA in the Balkan-AF cohort (as reflected by a low proportion of patients with a TTR of ≥65% and high proportion of patients with labile INRs) is particularly worrisome and calls for urgent action, as suboptimal TTR (\<65--70%) is associated with an excess of both stroke and bleeding (and mortality)[@b15][@b22][@b23]. Indeed, a TTR of \>70% is recommended in guidelines and position documents, when VKAs are used[@b15]. Also, missing TTR in \>80% of patients in the Balkan-AF cohort might indicate that the calculation of TTR is not commonly used in routine clinical practice in Balkan countries. Given the low quality of therapy with VKA compared to other European countries[@b24], increasing use of NOACs (17% of all patients taking OAC) is encouraging, as it could facilitate adequate stroke prevention in Balkan countries. An analysis of factors influencing the choice of NOAC over VKA in Balkan countries is underway.

This study is limited by its observational snapshot registry design, but we made every effort to include consecutive patients. Although we tried to capture a sample representative of real-world clinical practice by recruiting a range of different types of centres in each country (i.e., university and non-university hospitals and outpatient centres in- and outside the capital cities), there still may be a selection bias due to variable health care setting in the participating countries.

The proportion of cardiologists versus internal medicine specialists participating in the Balkan-AF survey may not fully reflect daily practice in the participating countries, since we might have not adequately covered the rural areas. Still, participating centres situated outside capital cities enrolled about 55% of patients, and in smaller countries many AF patients are often referred to the tertiary centres at least for initial evaluation.

Since TTR was available in a small proportion of patients treated with OAC, our results may under- or overestimate the quality of VKA treatment in our cohort, and we cannot conclude whether or not VKA therapy is systematically monitored in clinical practice.

Conclusion
==========

This survey provide important insights into contemporary routine practices for stroke prevention in AF patients in Balkan countries, thus reducing a gap in the European 'map' of contemporary real world management of AF. Our results show a broadly similar patient stroke risk profile in the Balkan Region and similar OAC use as in other European countries. However, routine practices for stroke prevention in AF patients in Balkan countries are less influenced by the presence of conventional well documented stroke risk factors in AF patients, and the quality of VKA therapy is low. Thus, additional efforts are needed to increase the adherence to AF guidelines and improve the management of AF-related risk of stroke in routine clinical practice in the Balkan Region.
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###### Patient demographic data, clinical characteristics and AF characteristics.

                                               Total         Albania          B&H          Bulgaria       Croatia       Montenegro      Romania         Serbia
  ---------------------------------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  *Demographic*                                                                                                                                     
   Age, years (mean ± SD)                   69.1 ± 10.9    68.2 ± 10.2    69.2 ± 10.6    70.2 ± 10.7    69.6 ± 11.1    65.0 ± 10.8    70.9 ± 10.8    67.4 ± 11.0
   Age ≥ 65--74 years (%)                    878 (33.0)     114 (36.4)     99 (37.4)      139 (31.4)     46 (28.9)      39 (38.2)      215 (30.8)     226 (33.1)
   Age ≥ 75 years (%)                        942 (35.4)     94 (30.0)      87 (32.8)      176 (39.7)     62 (39.0)      20 (19.6)      301 (43.1)     202 (29.6)
   Age ≥ 80 years (%)                        418 (17.7)     39 (12.5)      40 (15.1)      76 (17.2)      31 (19.5)       6 (5.9)       143 (20.5)     83 (12.2)
   Female sex (%)                           1188 (44.6)     151 (48.2)     115 (43.4)     189 (42.7)     67 (42.1)      35 (34.3)      325 (46.5)     306 (44.9)
   Cigarette smoking ever (%)                776 (29.1)     111 (35.5)     66 (24.9)      102 (23.0)     48 (30.2)      38 (37.3)      154 (22.0)     257 (37.7)
   Cigarette smoking current (%)             339 (12.7)     74 (23.6)      32 (12.1)      48 (10.8)      29 (18.2)      22 (21.6)       58 (8.3)      76 (11.1)
   Alcohol abuse (%)                         110 (4.1)       30 (9.6)       9 (3.4)        35 (7.9)       4 (2.5)        0 (0.0)        20 (2.9)       12 (1.8)
   Body mass index (mean ± SD)               27.7 ± 4.4     28.0 ± 3.9     26.8 ± 4.3     27.9 ± 3.8     27.8 ± 3.4     27.3 ± 3.7     28.5 ± 5.1     27.2 ± 4.3
   Systolic BP, mmHg (mean ± SD)            134.6 ± 22.0   131.5 ± 25.0   133.3 ± 24.6   135.2 ± 19.0   137.5 ± 19.3   137.7 ± 19.6   136.2 ± 24.0   133.4 ± 19.8
   Diastolic BP, mmHg (mean ± SD)           81.0 ± 12.2    81.4 ± 13.7    81.5 ± 12.7    81.6 ± 11.1    83.6 ± 10.0    86.8 ± 10.7    78.8 ± 13.1    81.0 ± 11.4
  *Characteristics of AF*                                                                                                                           
   First diagnosed AF (%)                    626 (23.5)     107 (34.4)     92 (34.7)      109 (24.6)     21 (13.2)      22 (21.6)      146 (20.9)     129 (18.9)
  *Known history of AF*                                                                                                                             
   Paroxysmal (%)                            554 (27.2)     43 (21.0)      23 (13.3)      77 (23.1)      45 (32.6)      31 (38.8)      106 (19.2)     229 (41.4)
   Persistent (%)                            319 (15.7)      13 (6.3)       12 (6.9)      72 (21.6)      46 (33.3)      13 (16.2)      77 (13.9)      86 (15.6)
   Long-standing persistent (%)               64 (3.1)       7 (3.4)        12 (6.9)       7 (2.1)        6 (4.3)        1 (1.2)        9 (1.6)        22 (4.0)
   Permanent (%)                            1081 (53.1)     142 (69.3)     126 (72.8)     178 (53.2)     41 (29.7)      34 (42.5)      360 (65.1)     200 (36.2)
  *Clinical parameters*                                                                                                                             
   Arterial hypertension (%)                2108 (79.2)     218 (69.6)     210 (79.2)     398 (89.8)     127 (79.9)     75 (73.5)      518 (74.1)     562 (82.4)
   Heart failure ever (%)                   1157 (43.5)     137 (43.8)     129 (48.9)     230 (51.9)     52 (32.7)       5 (4.9)       465 (66.6)     163 (23.9)
   Signs of heart failure at present (%)    1104 (41.5)     113 (36.1)     129 (48.9)     223 (50.3)     34 (21.4)       3 (2.9)       454 (65.0)     124 (18.9)
   Coronary artery disease (%)               816 (30.7)     99 (31.6)      106 (40.0)     147 (33.2)     35 (22.0)      16 (15.7)      256 (36.7)     157 (23.1)
   Prior PCI/stenting (%)                    224 (8.4)      35 (11.2)       6 (2.3)       62 (14.0)       9 (5.7)        8 (7.8)        50 (7.2)       54 (7.9)
   Prior CABG (%)                             97 (3.6)       12 (3.8)       13 (4.9)       17 (3.8)       3 (1.9)        1 (1.0)        15 (2.1)       36 (5.3)
   Prior myocardial infarction (%)           365 (13.7)     50 (16.0)      53 (20.0)       40 (9.0)       13 (8.2)       8 (7.8)       115 (16.6)     86 (12.6)
   Stable coronary artery disease (%)        592 (22.0)     64 (20.4)      100 (37.7)     85 (19.2)      26 (16.4)       8 (7.8)       206 (29.5)     103 (15.1)
   Valvular disease (%)                      933 (35.0)     69 (22.0)      60 (22.6)      159 (35.9)     39 (24.5)       3 (2.9)       414 (59.2)     189 (27.7)
   Mitral valve disease (%)                  844 (31.7)     53 (16.9)      54 (20.4)      131 (29.6)     34 (21.4)       1 (1.0)       388 (55.5)     183 (26.8)
   Mitral valve regurgitation (%)            818 (30.7)     53 (16.9)      51 (19.2)      127 (28.7)     33 (20.8)       1 (1.0)       381 (54.5)     172 (25.2)
   Aortic valve disease (%)                  299 (11.2)      28 (8.9)       23 (8.7)      66 (14.9)       8 (5.0)        2 (2.0)       131 (18.7)      41 (6.0)
   Dilated cardiomyopathy (%)                216 (8.1)       21 (6.7)       14 (5.3)       8 (1.8)       18 (11.3)       1 (1.0)       100 (14.3)      54 (7.9)
   Hyperthrophic cardiomyopathy (%)           52 (2.0)       6 (1.9)        12 (4.5)       2 (0.5)        4 (2.5)        0 (0.0)        20 (2.9)       8 (1.2)
   Restrictive cardiomyopathy (%)             4 (0.2)        0 (0.0)        0 (0.0)        0 (0.0)        1 (0.6)        0 (0.0)        3 (0.4)        0 (0.0)
   Congenital heart disease (%)               7 (0.3)        0 (0.0)        0 (0.0)        1 (0.2)        0 (0.0)        0 (0.0)        2 (0.3)        4 (0.6)
   Other cardiac disease (%)                 206 (7.7)       11 (3.5)       8 (3.0)        9 (2.0)        4 (2.5)        0 (0.0)       92 (13.2)      82 (12.0)
   Peripheral arterial disease (%)           122 (4.6)       13 (4.2)       7 (2.7)        19 (4.3)       5 (3.1)        2 (2.0)        40 (5.7)       36 (5.3)
   Diabetes mellitus (%)                     666 (25.0)     99 (31.6)      76 (28.7)      109 (24.6)     30 (18.9)      19 (18.6)      178 (25.5)     155 (22.7)
   Chronic kidney disease (%)                411 (15.5)     36 (11.5)      33 (12.5)      78 (17.6)      21 (13.3)       1 (1.0)       164 (23.5)     78 (11.5)
   Chronic hepatic disease (%)                96 (3.6)       7 (2.2)        9 (3.4)        13 (2.9)       2 (1.3)        0 (0.0)        54 (7.7)       11 (1.6)
   Prior stroke (%)                          280 (10.5)      29 (9.3)      40 (15.1)      47 (10.6)       13 (8.2)       7 (6.9)        65 (9.3)      79 (11.6)
   Prior TIA (%)                              83 (3.1)       16 (5.1)       18 (6.8)       14 (3.2)       5 (3.1)        0 (0.0)        14 (2.0)       16 (2.3)
   Prior bleeding (%)                        135 (5.0)       17 (5.4)       18 (6.8)       19 (4.3)       3 (1.9)        0 (0.0)        40 (5.7)       35 (5.0)
   CHA~2~DS~2~-VASc score                   3.48 ± 1.78    3.37 ± 1.79    3.66 ± 1.78    3.71 ± 1.76    3.21 ± 1.89    2.54 ± 1.61    3.81 ± 1.64    3.20 ± 1.76
   HASBLED score                            1.97 ± 1.23    1.87 ± 1.28    1.91 ± 1.18    1.92 ± 1.12    1.77 ± 1.17    1.87 ± 1.22    2.25 ± 1.26    1.86 ± 1.23

B&H: Bosnia & Herzegovina; SD: standard deviation; BP: blood pressure; AF: atrial fibrillation; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; TIA: transient ischemic attack.

###### Country-specific distribution of OAC and antiplatelet therapies.

                                              Total         Albania      B&H          Bulgaria     Croatia      Montenegro   Romania      Serbia
  ------------------------------------------- ------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  No antithrombotic therapy (%)               264 (9.9)     23 (7.3)     28 (10.6)    46 (10.4)    15 (9.4)     11 (10.8)    67 (9.6)     74 (10.9)
  Oral anticoagulant therapy-overall (%)      1960 (73.6)   229 (73.2)   133 (50.2)   319 (72.0)   134 (84.3)   72 (70.6)    534 (76.4)   539 (79.0)
  VKAs (%)                                    1662 (60.9)   205 (65.5)   111 (41.9)   191 (43.1)   110 (69.2)   68 (66.7)    482 (69.0)   455 (66.7)
  NOACs (%)                                   338 (12.7)    24 (7.7)     22 (8.3)     128 (28.9)   24 (15.1)    4 (3.9)      52 (7.4)     84 (12.3)
  Oral anticoagulant therapy alone (%)        1637 (61.5)   162 (51.8)   124 (46.8)   286 (64.6)   121 (76.1)   50 (49.0)    446 (63.8)   448 (65.7)
  Antiplatelet therapy (%)                    762 (28.6)    128 (40.9)   113 (42.6)   111 (25.1)   23 (14.5)    41 (40.2)    186 (26.6)   160 (23.5)
  Single antiplatelet drug only (%)           320 (12.0)    39 (12.5)    88 (33.2)    54 (12.2)    9 (5.7)      14 (13.7)    61 (8.7)     55 (8.1)
  DAPT only (%)                               119 (4.5)     22 (7.0)     16 (6.0)     24 (5.4)     1 (0.6)      5 (4.9)      37 (5.3)     14 (2.1)
  Dual therapy[a](#t2-fn1){ref-type="fn"}     240 (9.0)     51 (16.3)    9 (3.4)      17 (3.8)     9 (5.7)      14 (13.7)    74 (10.6)    66 (9.7)
  Triple therapy[b](#t2-fn2){ref-type="fn"}   83 (3.1)      16 (5.1)     0 (0.0)      16 (3.6)     4 (2.5)      8 (7.8)      14 (2.0)     25 (3.7)

B&H: Bosnia & Herzegovina; OAC: oral anticoagulant; VKA: vitamin-K antagonist; NOAC: non-vitamin K antagonist; DAPT: dual antiplatelet therapy.

^a^Dual therapy: OAC plus single antiplatelet agent.

^b^Triple therapy: OAC plus dual antiplatelet therapy.

###### Determinants of the use of antithrombotic therapies for stroke prevention in AF patients (see also Supplemental [Table 2](#t2){ref-type="table"}--5).

  Antithrombotic therapy              Univariate analysis (significant variables only)   Multivariate analysis   Antithrombotic therapy   Multivariate analysis                                                                               
  ----------------------------------- -------------------------------------------------- ----------------------- ------------------------ ----------------------- ------------ --------- ------------------------------- ------ ------------- ---------
  HASBLED (cont. variable)            1.08                                               1.01--1.16              0.042                                                                   PCI                             4.47   2.69--7.43    \<0.001
  Age≥80 years                        0.62                                               0.50--0.78              \<0.001                  0.54                    0.37--0.79   0.002     Coronary artery disease (any)   9.67   5.81--16.10   \<0.001
  Hypertension                        1.67                                               1.36--2.05              \<0.001                  1.85                    1.30--2.63   0.001     COPD                            1.95   1.14--3.33    0.015
  Prior MI                            0.47                                               0.36--0.61              \<0.001                  0.58                    0.37--0.91   0.018     Known history of AF             0.45   0.28--0.72    0.001
  Prior PCI                           0.32                                               0.22--0.47              \<0.001                                                                 Paroxysmal AF                   2.31   1.45--3.69    \<0.001
  Coronary artery disease (any)       0.49                                               0.41--0.60              \<0.001                                                                                                                       
  Stable coronary artery disease      0.55                                               0.46--0.67              \<0.001                                                                                                                       
  Mitral valve disease                1.40                                               1.15--1.70              0.001                    1.56                    1.07--2.28   0.021                                                           
  Dilated cardiomyopathy              2.06                                               1.40--3.04              \<0.001                  1.72                    1.10--2.68   0.018     *Dual or triple therapy*        OR     95%CI         P
  CKD on dialysis                     0.16                                               0.04--0.60              0.007                                                                   Age≥80 years                    0.58   0.39--0.88    0.009
  COPD                                0.73                                               0.57--0.94              0.016                                                                   PCI                             3.69   2.46--5.46    \<0.001
  Thyroid disease                     1.54                                               1.13--2.11              0.007                                                                   Coronary artery disease (any)   2.78   1.94--4.00    \<0.001
  Known history of AF                 2.53                                               2.07--3.08              \<0.001                  1.51                    1.04--2.20   0.032     Hospital--based centre          2.99   1.51--5.91    0.002
  Paroxysmal AF                       0.38                                               0.32--0.46              \<0.001                  0.44                    0.32--0.62   \<0.001   HASBLED (cont. variable)        1.24   1.11--1.38    \<0.001
  Body mass index                     1.06                                               1.04--1.08              \<0.001                  1.04                    1.01--1.08   0.031                                                           
  Centre in the capital city          2.02                                               1.68--2.43              \<0.001                  2.14                    1.50--3.05   \<0.001                                                         
  University centre                   2.09                                               1.62--2.69              \<0.001                                                                                                                       
  Cardiologist                        1.55                                               1.26--1.92              \<0.001                                                                                                                       
  *Antiplatelet drug only*            OR                                                 95%CI                   P                        OR                      95%CI        P         OAC (alone or in combination)   OR     95%CI         P
  CHA~2~DS~2~-VASc (cont. variable)   1.08                                               1.01--1.16              0.021                                                                   HASBLED≥3                       1.28   1.02--1.61    0.036
  Age ≥80 years                       1.88                                               1.42--2.49              \<0.001                  1.99                    1.46--2.73   \<0.001   Hypertension                    1.76   1.40--2.22    \<0.001
  Coronary artery disease (any)       1.63                                               1.26--2.10              \<0.001                  1.35                    1.03--1.77   0.033     Age≥80 years                    0.52   0.39--0.67    \<0.001
  Stable coronary artery disease      1.59                                               1.23--2.07              \<0.001                                                                 Coronary artery disease (any)   0.74   0.60--0.92    0.007
  Aortic valve disease                2.52                                               1.64--3.86              \<0.001                  1.52                    1.06--2.17   0.022     Mitral valve disease            1.29   1.03--1.62    0.030
  Other cardiac disease               0.50                                               0.28--0.90              0.021                                                                   Dilated cardiomyopathy          1.76   1.15--2.67    0.009
  Prior TIA                           1.78                                               1.01--3.13              0.047                                                                   Thyroid disease                 1.57   1.10--2.25    0.013
  COPD                                1.56                                               1.13--2.16              0.007                    1.55                    1.09--2.19   0.014     Known history of AF             1.50   1.16--1.93    0.002
  Body mass index                     0.96                                               0.93--0.99              0.003                    0.97                    0.94--0.99   0.033     Paroxysmal AF                   0.32   0.24--0.42    \<0.001
  Known history of AF                 0.57                                               0.43--0.74              \<0.001                  0.68                    0.51--0.91   0.010     Body mass index                 1.06   1.03--1.08    \<0.001
  Paroxysmal AF                       1.91                                               1.50--2.48              \<0.001                  2.42                    1.84--3.20   \<0.001   Centre in the capital city      1.98   1.58--2.49    \<0.001
  Centre in the capital city          0.45                                               0.34--0.59              \<0.001                  0.40                    0.30--0.54   \<0.001   Treatment by a cardiologist     1.37   1.06--1.78    0.016
  Treatment by a cardiologist         0.68                                               0.51--0.90              0.007                    0.67                    0.50--0.91   0.010                                                           

OAC: oral anticoagulant; OR: Odds Ratio; CI: Confidence Interval; DAPT: dual antiplatelet drug therapy; AF: atrial fibrillation; MI: Myocardial infarction; PCI: percutaneous coronary intervention; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; TIA: transient ischemic attack.
